Jafron Biomedical Co.,Ltd. / Fundamentals
Income statement
- Net revenue
€280.31M - Cost of goods sold
€54.75M - Gross profit
€225.56M - SG&A expenses
€49.44M - R&D expenses
€27.20M - EBITDA
€104.88M - D&A
€0.00 - EBIT
€102.82M - Interest expenses
€7.02M - EBT
€97.86M - Tax expenses
€18.94M - Net income
€79.56M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€53.06M - Changes in working capital
€0.00 - Operating cash flow
€82.00M - Capex
€23.70M - Other investing cash flow
€256.26K - Net investing cash flow
-€109.18M - Total cash dividends paid
-€78.54M - Issuance of common stock
€0.00 - Debt repayment
-€38.78M - Other financing cash flow
-€190.50K - Net financing cash flow
-€117.51M - Foreign exchange effects
€51.57K - Net change in cash
-€124.98M - Cash at end of period
€84.30M - Free cash flow
€105.70M
Balance sheet
- Cash and cash equivalents
€90.47M - Cash and short-term investments
€264.91M - Total receivables
€6.99M - Inventory
€39.73M - Other current assets
€7.19M - Total current assets
€318.82M - Property, plant & equipment
€232.20M - Goodwill
€848.49K - Intangible assets
€11.80M - Long-term investments
€51.99M - Other non-current assets
€15.26M - Total non-current assets
€318.66M - Total assets
€637.48M - Accounts payable
€14.58M - Short-term debt
€5.57M - Other current liabilities
€57.66M - Total current liabilities
€89.51M - Long-term debt
€139.67M - Deferred tax liabilities
€2.31M - Other non-current liabilities
€747.12K - Total non-current liabilities
€170.07M - Total liabilities
€259.59M - Common stock
€96.65M - Retained earnings
€276.49M - Other equity
€73.11M - Total equity
€377.90M - Total liabilities and shareholders' equity
€637.48M
Company information
- Market capitalization
€1.96B - Employees
2.8K - Enterprise Value
€17.26B
Company ratios
- Gross margin
-
80.5% Better than peer group: 69.0% - EBITDA margin
-
37.4% Even with peer group: 34.2% - EBIT margin
-
36.7% Better than peer group: 30.3% - EBT margin
-
34.9% Even with peer group: 30.6% - Net margin
-
28.4% Even with peer group: 24.4% - ROE
-
21.1% Even with peer group: 16.4% - ROA
-
12.5% Even with peer group: 11.8% - Asset turnover
-
44.0% Even with peer group: 48.9% - FCF margin
-
20.8% Better than peer group: 8.3% - FCF yield
3.0% - Efficiency ratio
62.6% - Net sales per employee
-
€100.22K - Net income per employee
-
€28.45K